Niranjan Sudhakar

发表

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

Kwok-Kin Wong, J. Fernandez-Banet, A. Pavlícek, 2021, Molecular Cancer Therapeutics.

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

J. Blake, J. Christensen, B. Brandhuber, 2018, ACS medicinal chemistry letters.

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

J. Christensen, J. Lawson, Jacob R. Haling, 2022, Journal of medicinal chemistry.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

J. Blake, J. Christensen, G. Vigers, 2020 .

Abstract LB-C09: The KRASG12Cinhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model

J. Fernandez-Banet, A. Pavlícek, J. Christensen, 2019 .

The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

David M. Woods, J. Christensen, D. Woods, 2018, Cancer Immunology, Immunotherapy.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

J. Fernandez-Banet, A. Pavlícek, J. Christensen, 2019, Cancer discovery.

Direct Evidence of Solution-Mediated Superoxide Transport and Organic Radical Formation in Sodium-Oxygen Batteries.

L. Nazar, J. Baugh, R. Fernandes, 2016, Journal of the American Chemical Society.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.

G. Vigers, J. Gaudino, Jennifer N. Otten, 2020, Journal of medicinal chemistry.

TEAD Inhibition Overcomes YAP1/TAZ-driven Primary and Acquired Resistance to KRASG12C Inhibitors.

C. Der, Andrew M. Waters, Jill Hallin, 2023, Cancer research.